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Introduction {#sec1}
============

HNF4A (HNF4α, NR2A1) is a transcription factor that belongs to the nuclear hormone receptor superfamily. HNF4A plays a critical role in development, cell differentiation, and metabolism, particularly in the visceral endoderm, liver, intestine, kidney, and pancreatic β cells. The most important target genes of HNF4A belong to glucose, lipid, and drug metabolism pathways ([@bib9], [@bib17], [@bib34]). Like all other nuclear hormone receptors, HNF4A has a ligand-binding domain and a DNA-binding domain (LBD and DBD, respectively). Long considered an orphan receptor, the LBD of HNF4A binds fatty acids in a reversible fashion, as suggested by several reports ([@bib14], [@bib51]). The highly conserved DBD recognizes the bipartite direct repeat 1 (DR1) consensus sequence that is present in a great variety of target genes ([@bib17]). Although HNF4A only dimerizes with itself and not with other nuclear receptors ([@bib22]), it was recently shown that an increase in functional diversity can be achieved by the dimerization of different splice variants ([@bib29]). The levels of nuclear HNF4A are regulated by protein kinase C (PKC)-dependent phosphorylation of a serine residue at position 87 in the DNA-binding domain, leading to enhanced nuclear export and proteasomal degradation ([@bib47]).

More than 2 decades ago, mutations in the *HNF4A* gene were identified as the first monogenic cause of maturity-onset diabetes of the young type 1 (MODY1) ([@bib52]), usually diagnosed before the age of 25 years in patients with negative islet cell autoantibodies. Additional MODY genes are *HNF1A* and *HNF1B*, which functionally interact with HNF4A, thereby defining a transcriptional network responsible for phenotypically indistinguishable forms of MODY ([@bib16]). Thus far, ∼100 MODY1 mutations have been described for the coding region of *HNF4A* ([@bib2]). All of them are dominant mutations, considered to be haploinsufficient ([@bib18]). One specific missense mutation in the DNA-binding domain, p.R85W, causes additional defects in the proximal tubules of the kidney or Fanconi renotubular syndrome (FRTS; OMIM: [616026](616026){#intref0010}; note that due to differences in genome annotations, this mutation has also been called R76W and R63W). This mutation has been reported in 15 cases from 12 unrelated families with full penetrance of the FRTS in the carriers ([@bib13], [@bib19], [@bib21], [@bib32], [@bib37], [@bib46], [@bib49]). In the kidney, HNF4A is exclusively expressed in proximal tubules ([@bib35]). However, why only the R85W mutation in HNF4A causes FRTS remains unclear.

The proximal tubule is situated close to the glomerulus and is required for the extensive reabsorption of water, electrolytes, and specific organic solutes. This includes low-molecular-weight (LMW) proteins, protein-bound lipids, amino acids, glucose, bicarbonate, and phosphate. Uptake occurs via receptor-mediated endocytosis or transepithelial transport, which requires an unusually high amount of energy in the form of ATP. In proximal tubule cells, ATP is for the most part generated by mitochondrial β-oxidation of fatty acids ([@bib25]), which are mostly taken up from the environment ([@bib4]). FRTS, a failure of proximal tubular function, is therefore featured by LMW proteinuria, glucosuria, aminoaciduria, and phosphaturia, with some forms leading to end-stage renal disease. The most common are genetic forms affecting endolysosomal or mitochondrial functions ([@bib28]).

In *Drosophila*, HNF4A is well conserved (dHNF4), and its inactivation causes the accumulation of lipid droplets (LDs) in various tissues due to reduced mitochondrial function ([@bib7], [@bib39]). Here, we used *Drosophila* nephrocytes as a model for proximal tubules to study the function of HNF4A and the impact of the FRTS-associated R85W mutation. These cells are specialized in the reabsorption of components from the hemolymph ([@bib20], [@bib50]). The reabsorption includes filtration via slit diaphragms and then, similar to proximal tubular cells, endocytic uptake via the LMW receptors cubilin and amnionless ([@bib20], [@bib54]). We found that that the expression of dHNF4 harboring the FRTS mutation affects the catabolism of LDs in nephrocytes by interfering with mitochondrial function, which could be confirmed in a mammalian renal epithelial system ([@bib24]). Moreover, we showed that the FRTS mutation promotes the nuclear export of a wild-type reporter protein, thereby reducing transcriptional output in a dominant-negative manner and promoting the formation of cytotoxic dHNF4 aggregates in the cytosol. The cytotoxic effects could be suppressed by inhibiting nuclear exit and proteasomal degradation of dHNF4. By contrast, the expression of another known close mutation in the DBD, R89W (that leads to MODY1 but not to FRTS; [@bib19]), did not cause any dominant-negative or cytotoxic effects. Our data shed light on the molecular basis for the unique effects of the FRTS mutation, with implications for lipid metabolism in proximal tubules and for the control of other nuclear hormone receptors.

Results {#sec2}
=======

dHNF4 Controls LD Content and Mitochondria in Nephrocytes {#sec2.1}
---------------------------------------------------------

Nephrocytes exist in two functionally equivalent populations, one close to the gut (garland nephrocytes) and one close to the heart (pericardial nephrocytes) ([Figure 1](#fig1){ref-type="fig"}A). An advantage of the garland nephrocytes is that they can easily be dissected and studied *ex vivo.* The expression and active state of dHNF4 in the nuclei of garland nephrocytes was addressed by two different reporter lines: the first expresses GFP-tagged dHNF4 under its native promoter and was shown to rescue the lethality of a *dHNF4* null mutant ([@bib40]); the second reporter line expresses a chimeric protein obtained by the fusion of the DBD of GAL4 and the LBD of dHNF4, which, when activated, drives the expression of a *lacZ* gene ([@bib39]). While dHNF4-GFP was readily expressed in the nuclei of garland nephrocytes and surrounding gut tissue ([Figure 1](#fig1){ref-type="fig"}B), the *lacZ* reporter was active only in nephrocytes, suggesting an important function of dHNF4 in these cells ([Figure 1](#fig1){ref-type="fig"}C).Figure 1dHNF4 Silencing Increases Lipid Droplet Content and Causes Mitochondrial Dysfunction in *Drosophila* Nephrocytes(A) In *Drosophila* third instar larvae, garland nephrocytes (NPs) are tethered to the esophagus (Oe) and proventriculus (Pv) and pericardial nephrocytes are tethered to the heart.(B) Confocal section with insets showing garland nephrocytes expressing dHNF4-GFP under the native *dHNF4* promoter, stained for GFP and DNA. Scale bars, 10 μm, insets 5 μm.(C) Bright-field images of garland cells expressing a reporter for dHNF4 activation, stained for lacZ expression with X-gal. Scale bars, 10 μm.(D) Z-projections showing staining with BODIPY 493/503 for lipid droplets in nephrocytes expressing RNAi against *GFP* and *dHNF4*. Scale bars,10 μm, insets 5 μm.(E) Quantification of the cell area occupied by LDs per cell. Values were normalized to the average value in control nephrocytes. Scattered plot represents seven independent experiments and red lines represent medians. Mann-Whitney t test: ^∗∗∗∗^p \< 0.0001.(F) Quantification of the average LD density measured by the number of LDs per cell volume (two independent experiments, red lines: medians, Mann-Whitney t test: ^∗∗∗∗^p \< 0.0001).(G) Quantification of the average LD size. Values were normalized to the average value in control nephrocytes, and bars represent means ± SDs (two independent experiments, Mann-Whitney t test: ^∗∗∗∗^p \< 0.0001).(H) TEM sections of GFP and dHNF4-depleted nephrocytes. Scale bars, 1 μm.(I) Confocal sections of GFP and dHNF4-depleted nephrocytes stained for ATP5A and DNA. Scale bars, 10 μm, insets 5 μm.(J) Quantification of the ATP5A staining intensity. Values were normalized to the average value in control nephrocytes (four independent experiments, red lines: medians, Mann-Whitney t test: ^∗∗∗∗^p \< 0.0001).See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

To better understand the function of dHNF4 in nephrocytes, we studied LDs that were previously shown to accumulate in several tissues of starved *dHNF4* null mutants due to a reduction in mitochondrial β-oxidation ([@bib39]). LDs can be visualized by the lipophilic BODIPY dye that partitions into the triglyceride (triacylglycerol \[TAG\])- and cholesterylester-filled core of these cytoplasmic organelles. Transgenes were expressed with the UAS-GAL4 system ([@bib6]) using *Dorothy-*GAL4 (*Dot-*GAL4) and *Sns-*GAL4, both of which have previously been shown to drive expression in both nephrocyte populations ([@bib33], [@bib54], [@bib55], [@bib56]). We used two different control RNAi transgenes targeting *GFP* or the testis-specific *Pkd2* ([@bib30]). Compared to these control cells, depletion of *dHNF4* by two different RNAi lines (*dHNF4* knockdown \[KD\]) led to an increase in LD content, number, and size in all garland nephrocytes ([Figures 1](#fig1){ref-type="fig"}D--1G and [S1](#mmc1){ref-type="supplementary-material"}A--S1E), which could also be observed using transmission electron microscopy (TEM; [Figure 1](#fig1){ref-type="fig"}H). The mitochondria of *dHNF4*-depleted cells showed reduced amounts of ATP5A, which is a subunit of the mitochondrial ATP synthase in the respiratory chain ([Figures 1](#fig1){ref-type="fig"}I, 1J, [S1](#mmc1){ref-type="supplementary-material"}F, and S1G). Moreover, the accumulation of LDs in *dHNF4* KD cells could be suppressed by silencing *mdy* ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B), the ortholog of the endoplasmic reticulum (ER)-localized diacylglycerolacyltransferase 1 (DGAT1). In line with previous studies, these findings suggest that LD accumulation in nephrocytes is a result of reduced β-oxidation and subsequent DGAT1-dependent esterification of unmetabolized fatty acids into TAGs ([@bib12], [@bib36], [@bib39]).

Overexpression of dHNF4 Regulates LD in an Expression Level-Dependent Manner {#sec2.2}
----------------------------------------------------------------------------

In contrast to the KD, the overexpression of dHNF4 (dHNF4^OE^) significantly decreased LD content in most nephrocytes ([Figures 2](#fig2){ref-type="fig"}A and 2B, inset 2), indicating an increased use of storage lipids for mitochondrial β-oxidation. Some cells, however, exhibited the opposite phenotype with strong LD accumulations, as shown in inset 1 and by the outliers in the graph of [Figure 2](#fig2){ref-type="fig"}B. LD^+^ cells showed an increase in the area covered by LDs that was, unlike *dHNF4* KD, not due to an increase in size but to an augmented LD number per cell volume ([Figures 2](#fig2){ref-type="fig"}C--2E). An enhanced ATP5A staining was observed in LD^−^ cells, but not in LD^+^cells ([Figures 2](#fig2){ref-type="fig"}F and 2G), supporting the functional correlation between LD content and mitochondrial respiratory chain activity.Figure 2dHNF4 Overexpression Decreases Lipid Droplet Content(A) Z-projections with insets showing LD and DNA staining in control and dHNF4-overexpressing nephrocytes. Scale bars, 10 μm, insets 5 μm.(B) Quantification of the cell area covered by LDs per cell. Values were normalized to the average value in control nephrocytes (five independent experiments, red lines: medians, Mann-Whitney t test: ^∗∗∗∗^p \< 0.0001).(C) Quantification of the average LD density (number of LDs per cell volume) in control and dHNF4-overexpressing nephrocytes (three independent experiments, red lines: medians, Mann-Whitney t test: ^∗∗∗∗^p \< 0.0001).(D) Quantification of the average LD size. Values were normalized to the average value in control nephrocytes and bars represent means ± SDs (three independent experiments, red lines: medians, Mann-Whitney t test: non-significant \[ns\]).(E) TEM sections of an LD^−^ and an LD^+^ dHNF4-overexpressing nephrocyte. Scale bars, 1 μm.(F) Confocal sections of dHNF4-overexpressing nephrocytes, stained for LD, ATP5A, and DNA. Scale bars, 10 μm, insets 5 μm.(G) Quantification of the ATP5A staining intensity in LD^−^ and LD^+^ cells shown in (F). Values were normalized to the average value in control nephrocytes (five independent experiments, red lines: medians, one-way ANOVA test: ^∗∗∗∗^p \< 0.0001, ^∗∗^p \< 0.01, ns: non-significant).See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

To test whether the different LD phenotypes were dependent on the expression level of dHNF4, we made use of the temperature dependency of the UAS-GAL4 system ([Figure S3](#mmc1){ref-type="supplementary-material"}A) ([@bib15]). While low overexpression at 18°C showed complete LD depletion ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3D), switching the temperature to 29°C at L3 larval stages led to strong lipid accumulation ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3D) and low ATP5A levels in nephrocytes ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Hereafter, the three different expression levels are referred to as dHNF4^lowOE^ (18°C), dHNF4^OE^ (25°C), and dHNF4^highOE^ (29°C). While the temperature itself also increased LDs to some extent ([Figure S3](#mmc1){ref-type="supplementary-material"}D), dHNF4^highOE^ cells always had more LDs than the controls and dHNF4^lowOE^ always had fewer LDs ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3D). Moreover, co-expressing *mdy* RNAi with dHNF4 completely abolished LDs in both dHNF4^OE^ and dHNF4^highOE^ cells ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B), suggesting that similar to *dHNF4* KD, the increased LD amount, as in the KD, may be the result of unmetabolized fatty acids being diverted toward esterification and storage.

dHNF4^OE^ Leads to Nuclear Depletion of the Wild-Type Protomer {#sec2.3}
--------------------------------------------------------------

To better understand the phenotypic similarity between *dHNF4* RNAi and dHNF4^OE^, we studied the localization of the overexpressed dHNF4 in nephrocytes, making use of its hemagglutinin (HA) tag. We identified a spectrum of localization patterns that matched the LD phenotypes seen in each overexpression condition: normal nuclear localization was only found in all dHNF4^lowOE^ and LD^−^ dHNF4^OE^ cells ([Figures 3](#fig3){ref-type="fig"}A and 3B), whereas enrichment at the lamin D^+^ nuclear periphery was detected for LD^+^ dHNF4^OE^ cells ([Figure 3](#fig3){ref-type="fig"}A) and dHNF4^highOE^ cells ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}F). As HNF4A normally forms dimer, we also tested effects on the dHNF4-GFP reporter protein. We found that dHNF4^OE^ and dHNF4^highOE^ caused a mild and a strong reduction in nuclear dHNF4-GFP, respectively ([Figures 3](#fig3){ref-type="fig"}D and 3E). These data suggest that the phenotypic similarity between KD and dHNF4 overexpression may be explained by the loss of nuclear activity of the protomer expressed from the wild-type allele.Figure 3dHNF4^highOE^ Leads to Nuclear Depletion of the Wild-Type Protomer(A) Confocal sections of nephrocytes overexpressing dHNF4, stained for LD, DNA, and HA, and insets showing nuclei. Scale bars, 10 μm, insets 5 μm.(B and C) Confocal sections of representative nuclei stained for DNA and HA of nephrocytes overexpressing dHNF4 at 18°C (B) and 29°C (B and C). Scale bars, 5 μm.(D) Z-projections of nephrocytes expressing dHNF4-GFP under the native *dHNF4* promoter together with control RNAi or dHNF4-HA, at 25°C and 29°C, stained for GFP and DNA. Scale bars, 10 μm, insets 5 μm.(E) Quantification of the average nuclear GFP intensity in (D). Values were normalized to control nephrocytes at 25°C and 29°C (three independent experiments for each genotype, red bars: medians, one-way ANOVA test: ^∗∗^p \< 0.01, ^∗∗∗∗^p \< 0.0001).(F) TEM sections of dHNF4-overexpressing nephrocytes. Arrows point to autophagic structures. Black arrowheads point to electron-dense aggregates. White arrowheads point to multi-layering of autophagosomal membranes. Scale bars, 1 μm (first and second panels) and 500 nm (third and fourth panels).See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

dHNF4^OE^ Causes Cytotoxic Effects {#sec2.4}
----------------------------------

In dHNF4^highOE^ cells, the nuclear depletion of dHNF4 also correlated with the formation of cytoplasmic punctae that were positive for ubiquitin ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}G). As ubiquitinated aggregates normally stimulate autophagy, we looked at autophagic flux by using the GFP-mCherry-Atg8 tandem reporter (Atg8 corresponds to LC3 in mammals) ([@bib26]). We observed an increase in Atg8-GFP-mCherry signal in dHNF4^OE^ ([Figure S4](#mmc1){ref-type="supplementary-material"}A and insets). However, unlike the silencing of *ATP6AP2*, a subunit of the proton pump V-ATPase, this signal did not co-localize with GFP, suggesting that autophagic flux was enhanced ([Figure S4](#mmc1){ref-type="supplementary-material"}A and insets). By performing TEM on dHNF4^OE^ cells, we found abundant cytoplasmic phagophores and autophagosomes, whose limiting membranes were often multilamellar in structure ([Figure 3](#fig3){ref-type="fig"}F). Numerous electron-dense structures could be detected inside and outside the autophagosomes, possibly representing ribosomes or the aggregates themselves ([Figure 3](#fig3){ref-type="fig"}F). Furthermore, we found in control cells a perinuclear compact ER decorated with ribosomes, while ER structures were difficult to detect in dHNF4^OE^ cells ([Figure 3](#fig3){ref-type="fig"}F). This was confirmed by immunostaining for the luminal ER marker protein di-sulfide isomerase (PDI) displaying an abnormal ER expansion for LD^+^ dHNF4^OE^ and dHNF4^highOE^ ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4D), while the ER showed a normal perinuclear morphology in control cells and in dHNF4 KD and dHNF4^lowOE^ cells ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C).

The increase in autophagy and the ER abnormalities correlated well with the effects on the viability of nephrocytes and of the entire animal. With *sns-*GAL4, nephrocyte cytotoxicity became apparent already at L3 larval stage, causing a reduction in cell size and number in dHNF4^OE^ as compared to control ([Figure S4](#mmc1){ref-type="supplementary-material"}E). With *Dot-*GAL4 but not *Sns-*GAL4, there was also a reduced animal viability, suggesting that this driver also expresses in cells besides nephrocytes that are essential for survival. While animals expressing dHNF4 at 29°C were dying already at L3 larval stages, there was an intermediate phenotype at 25°C with animals that were able to survive into adulthood, albeit with a loss of nephrocytes ([Figure S4](#mmc1){ref-type="supplementary-material"}F). By contrast, the viability of nephrocytes and whole animals was unaffected in *dHNF4* KD- and dHNF4^lowOE^-expressing animals (data not shown).

The data suggest the following scenario: the higher the expression of dHNF4, the more nuclear export and formation of cytosolic aggregates, which in turn lead to ER damage, autophagy, and eventually cell death. As none of these cytotoxic effects were found for *dHNF4* KD, we conclude that they are related to the cytosolic aggregates of dHNF4^highOE^.

Blocking Degradation Signaling Prevents dHNF4^highOE^-Induced Phenotypes {#sec2.5}
------------------------------------------------------------------------

The nuclear export and turnover of HNF4A was previously shown to depend on PKC-dependent phosphorylation at the highly conserved serine 87 (S87) in the DBD ([Figure 4](#fig4){ref-type="fig"}A) ([@bib47]). We therefore reasoned that suppressing the phosphorylation may also suppress the loss of nuclear HNF4 and cytotoxic effects. To address this, we attempted to suppress phosphorylation by introducing a serine-to-alanine conversion at the corresponding 169 position in the fly sequence (dHNF4^S169A^; [Figure 4](#fig4){ref-type="fig"}A). To avoid any confounding positional effects, the UAS transgene was inserted at the same genomic position as the wild-type transgene. We first addressed the localization of this supposedly phospho-deficient form. dHNF4^S169A^ was nuclear at both 25°C and 29°C ([Figure 4](#fig4){ref-type="fig"}B), as was the dHNF4-GFP reporter ([Figures 4](#fig4){ref-type="fig"}C and 4D). Moreover, LD content was equally depleted as in dHNF4^lowOE^ cells ([Figures 4](#fig4){ref-type="fig"}E and 4F), and mitochondrial ATP5A was increased in dHNF4^S169A^ nephrocytes ([Figures 4](#fig4){ref-type="fig"}G and 4H), suggesting that dHNF4^S169A^ strongly promotes lipid catabolism. In addition, autophagy, ER morphology, and viability of nephrocytes were normal ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C). These data suggest that increasing nuclear dHNF4 levels by preventing nuclear export positively regulates lipid catabolism and mitochondrial function while suppressing any dominant-negative effects.Figure 4Blocking Degradation Signaling Prevents dHNF4-Induced Phenotypes(A) Region of the DNA-binding domain between the two zinc fingers containing the S87 in humans, corresponding to S169 in flies.(B) Confocal sections of representative nuclei stained for DNA and HA of nephrocytes overexpressing dHNF4^S169A^ at 25°C and 29°C. Scale bars, 5 μm.(C) Z-projections of nephrocytes expressing dHNF4-GFP under the native HNF4 promoter and dHNF4^S169A^ at 25°C and 29°C, stained for GFP, HA, and DNA. Scale bars, 10 μm, insets 5 μm.(D) Quantification of the average nuclear GFP intensity in (C), compared to that of control and dHNF4-overexpressing nephrocytes shown in [Figure 3](#fig3){ref-type="fig"}E. Values were normalized to control nephrocytes (three for 25°C and two for 29°C independent experiments, red lines: medians, one-way ANOVA test: ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, ns: non-significant).(E) Z-projections showing control and dHNF4^S169A^-overexpressing nephrocytes stained for LDs and DNA. Scale bars, 10 μm.(F) Quantification of the cell area occupied by lipid droplets per cell in the genotypes shown in (E) compared to the cell area of nephrocytes expressing dHNF4 shown in [Figure 2](#fig2){ref-type="fig"}B. Values were normalized to control nephrocytes (three independent experiments, red lines: medians, one-way ANOVA test, ^∗∗∗∗^p \< 0.0001.(G) Confocal sections of control and dHNF4^S169A^-overexpressing nephrocytes, stained for ATP5A and DNA. Scale bars, 10 μm, insets 5 μm.(H) Quantification of the ATP5A staining intensity shown in (G) compared to the staining intensity of nephrocytes expressing dHNF4 (LD^−^) shown in [Figure 2](#fig2){ref-type="fig"}G. Values were normalized to the average value in control nephrocytes (three for dHNF4^S169A^ and five for dHNF4^OE^ independent experiments, red lines: medians, one-way ANOVA test: ^∗∗∗∗^p \< 0.0001, ^∗∗^p \< 0.01).See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Renal Fanconi Syndrome-Associated *Drosophila* Mutation R167W Causes LD Accumulation and Mitochondrial Defects {#sec2.6}
--------------------------------------------------------------------------------------------------------------

Next, we investigated the impact of the MODY1 mutation R85W, which is uniquely associated with FRTS in humans. We compared its phenotypes to a nearby arginine-to-tryptophan substitution, R89W, that causes MODY1 without FRTS ([Figure 5](#fig5){ref-type="fig"}A) ([@bib19]). Previously, the crystal structure of human HNF4A had shown that both R85 and R89 are in close proximity to DNA and that replacing either of the arginines with tryptophan could impair DNA binding ([@bib5]). We confirmed this hypothesis by performing an electrophoretic mobility shift assay (EMSA) in COS-7 cells, showing that while HNF4 wild-type (WT) and S87A readily bound to a DNA probe with HNF4A target motif ([@bib22]), the binding of HNF4 R85W and R89W was strongly reduced ([Figure 5](#fig5){ref-type="fig"}B).Figure 5Renal Fanconi Syndrome-Associated Mutation dHNF4 (p.R167W) Causes Nuclear Depletion of the Wild-Type Protomer That Can Be Rescued by Blocking Degradation Signaling(A) Region of the DNA-binding domain between the two zinc fingers containing the human R85W mutation causing both MODY1 and Fanconi renotubular syndrome (FRTS) and the R89W mutation causing MODY1, corresponding to R167W and R171W, respectively, in flies. Below is the dHNF4 double mutant containing R167W/FRTS and S169A mutations (dHNF4^R167W/S169A^-HA).(B) EMSA of COS-7 nuclear extracts containing overexpressed HNF4A WT and mutants with the ApoAI site A probe.(C) Confocal sections of representative nuclei stained for DNA and HA of nephrocytes overexpressing dHNF4^R167W/FRTS^-HA, dHNF4^R171W/MODY^-HA, and dHNF4^R167W/S169A^-HA. Scale bars, 5 μm.(D) Z-projections of nephrocytes expressing dHNF4-GFP under the native *dHNF4* promoter together with dHNF4^R167W/FRTS^-HA, dHNF4^R171W/MODY^-HA, and dHNF4^R167W/S169A^-HA, stained for GFP and DNA. Scale bars, 10 μm, insets 5 μm.(E) Quantification of the average nuclear GFP intensity in (A). Values were normalized to control nephrocytes (four independent experiments for dHNF4^R167W/FRTS^-HA and dHNF4^R171W/MODY^-, three for dHNF4^R167W/S169A^-HA, red bars: medians, one-way ANOVA test: ^∗∗∗∗^p \< 0,0001, ns: non-significant).See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

In flies, the arginines in positions 85 and 89 correspond to the arginines in positions 167 and 171 ([Figure 5](#fig5){ref-type="fig"}A). We generated two UAS transgenes harboring the two mutations, respectively (hereafter called dHNF4^R167W/FRTS^ and dHNF4^R171W/MODY^). Nephrocytes expressing dHNF4^R167W/FRTS^ displayed either an enrichment of the HA staining at the nuclear periphery or a very weak staining in the nucleus ([Figure 5](#fig5){ref-type="fig"}C). Nuclear localization of dHNF4-GFP was completely lost, accompanied by a very strong increase in GFP^+^ puncta in the cytosol ([Figures 5](#fig5){ref-type="fig"}D and 5E). Accordingly, these cells displayed a strong increase in LDs ([Figures 6](#fig6){ref-type="fig"}A and 6B), which could be fully suppressed by *mdy* KD ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). In addition, mitochondrial ATP5A staining was strongly decreased ([Figures 6](#fig6){ref-type="fig"}C and 6D), while autophagy was increased and ER morphology strongly disturbed ([Figures 6](#fig6){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}G). When using the *Sns-*GAL4 driver nephrocyte, loss was already apparent at early larval stages ([Figure 6](#fig6){ref-type="fig"}F). When using the *dot-*GAL4 driver, there was also a strongly reduced animal lethality. In contrast to wild-type dHNF4, these phenotypes could even be observed at 18°C ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6F), indicating that the dominant-negative effects of dHNF4^R167W/FRTS^ are more severe than they are for dHNF4^OE^.Figure 6dHNF4^R167W/FRTS^ Causes LD Accumulation, Mitochondrial Defects, and Cytotoxic Effects That Can Be Rescued by Blocking Degradation Signaling(A) Z-projections showing LD and DNA staining in control, dHNF4^R167W/FRTS^-, dHNF4^R171W/MODY^-, or dHNF4^R167W/S169A^-overexpressing nephrocytes. Scale bars, 10 μm.(B) Quantification of the cell area occupied by LDs per cell in the genotypes shown in (A) (five independent experiments for dHNF4^R167W/FRTS^, three for dHNF4^R171W/MODY^ and dHNF4^R167W/S169A^, red lines: medians, one-way ANOVA test: ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, ns: non-significant).(C) Confocal sections showing nephrocytes expressing *GFP-RNAi*, dHNF4^R167W/FRTS^, HNF4^R171W/MODY^, or dHNF4^R167W/S169A^, stained for ATP5A and DNA. Scale bars, 10 μm, insets 5 μm.(D) Quantification of the ATP5A staining intensity shown in (C). Values were normalized to the average value in control nephrocytes (three independent experiments, red lines: medians, one-way ANOVA test ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, ns: non-significant).(E) Confocal sections showing PDI and DNA staining in nephrocytes expressing *GFP-RNAi*, dHNF4^R167W/FRTS^, dHNF4^R171W/MODY^, or dHNF4^R167W/S169A^. Scale bars, 10 μm, insets: 5 μm.(F) Z-projections of larval garland nephrocytes expressing *GFP-RNAi*, dHNF4^R167W/FRTS^, dHNF4^R171W/MODY^, or dHNF4^R167W/S169A^ driven by *Sns*-GAL4 and stained for DNA and for HRP-Cy3 staining nephrocyte membranes. Scale bars, 10 μm.See also [Figure S6](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

The expression of dHNF4^R171W/MODY^ caused no dominant-negative effects. Instead, the situation was highly similar to the expression of the phosphorylation-deficient dHNF4^S169A^: there was a normal nuclear distribution of both the transgene and dHNF4-GFP ([Figures 5](#fig5){ref-type="fig"}C--5E). Mitochondria staining, ER morphology, and viability were normal ([Figures 6](#fig6){ref-type="fig"}C--6F). Similar observations were made at 29°C ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6E). The only difference from dHNF4^S169A^ was that for dHNF4^R171W/MODY^, the LD content was only reduced and not fully eliminated ([Figure 6](#fig6){ref-type="fig"}A), which is in line with the reduced DNA binding in the EMSA assay ([Figure 5](#fig5){ref-type="fig"}B).

S169A Partially Rescues R167W/FRTS Phenotypes {#sec2.7}
---------------------------------------------

To prevent phosphorylation in both mutants, we created double mutants of S87A and R167/FRTS and R171W/MODY ([Figure 5](#fig5){ref-type="fig"}A). As expected, the nuclear localization of R171W/MODY was unaffected by the additional mutation (not shown). However, the expression of R167W/S169A double mutant showed a strong increase in nuclear levels compared to R167W alone ([Figure 5](#fig5){ref-type="fig"}C). The nuclear localization of dHNF4-GFP reporter ([Figures 5](#fig5){ref-type="fig"}D and 5E), the ER morphology ([Figure 6](#fig6){ref-type="fig"}E), and the autophagy levels ([Figure S6](#mmc1){ref-type="supplementary-material"}G) were entirely restored, suggesting suppressed dominant-negative effects. Moreover, S169A caused a striking restoration of the viability of the whole animal when using *Dot-*GAL4 (data not shown) and of nephrocytes when using *Sns-*GAL4 as drivers ([Figure 6](#fig6){ref-type="fig"}F). Although mitochondrial ATP5A levels seemed normalized ([Figures 6](#fig6){ref-type="fig"}C and 6D), LD content remained high in the R167W/S169A double mutant ([Figures 6](#fig6){ref-type="fig"}A and 6B), suggesting that the dephosphorylation cannot rescue the decreased transcriptional activity. This was supported by the finding that the R85W/S87A double mutant showed almost no detectable DNA binding in the EMSA shift assay ([Figure 5](#fig5){ref-type="fig"}B). Therefore, our data demonstrate that preventing the mutant protein from being phosphorylated at S169 and expelled from the nucleus for degradation strongly diminishes all dominant-negative effects of dHNF4 without rescuing lipid metabolism defects ([Table S1](#mmc1){ref-type="supplementary-material"}).

R85W/FRTS Mutation Causes Mitochondrial Dysfunction in Mouse Reprogrammed Renal Epithelial-like Cells {#sec2.8}
-----------------------------------------------------------------------------------------------------

Finally, to validate the effects of the FRTS mutation in a mammalian model, we chose a direct reprogramming approach, called induced renal epithelial cells (iRECs) ([@bib24]), in which HNF4A is one of three transcription factors inducing renal epithelial cell fate ([Figure 7](#fig7){ref-type="fig"}A). In this system, HNF4A is particularly important for the expression of several proximal tubular markers ([@bib24]), which is in agreement with *in vivo* mouse studies ([@bib35]). Embryonic fibroblasts were isolated from mouse embryonic fibroblasts (MEFs) harboring Cre-recombinase under the control of the renal tubule-specific cadherin-16 promoter (Cdh16/Ksp-Cre) and the tandem dimer Tomato red/EGFP (tdTomato/EGFP) dual fluorescent reporter ([@bib44]). Upon lentiviral transduction with Pax8, Hnf1b, and HNF4A (wild-type or R85W/FRTS), cells that had switched from Tomato to EGFP expression and thus had acquired renal cell fate were isolated by fluorescence-activated cell sorting (FACS) and then functionally characterized ([Figure 7](#fig7){ref-type="fig"}A).Figure 7Direct Reprogramming of Mouse Embryonic Fibroblasts to iRECs Using HNF4A R85W(A) Schematic representation of the reprogramming strategy. Mouse embryonic fibroblasts (MEFs) were isolated from the limbs of Ksp-Cre/dtTomato;EGFP E13.5 pups and transduced with the indicated transcription factor cocktails.(B) Relative mRNA expression level of exogenous HNF4A in iRECs HNF4A^WT^-V5 and iRECs HNF4A^R85W^-V5. qPCR primers encompass the V5 region and parts of the coding sequence of transduced HNF4A. Values were normalized to the mTBP housekeeping gene (Mann-Whitney t test: ^∗∗^p \< 0.01).(C) Immunostainings of the V5-tag in HNF4A^WT^-V5 and HNF4A^R85W^-V5 iRECs. Scale bar, 10 μm.(D) Quantification of the nuclear staining normalized to the average value of iRECs WT (three independent experiments, red lines: medians, Mann-Whitney t test, ^∗∗∗∗^p \< 0.0001).(E) Heatmap of the significant differentially expressed genes (DEGs) (N = 10,963) between all three analyzed conditions. Each row represents a gene. Each column represents one of three biological replicates per reprogramming condition. FPKM, fragments per kilobase million.(F) GO overrepresentation analysis using clusterProfiler. In the schematic depiction of the cluster categories, the first dot represents MEFs (A), the second dot represents iRECs HNF4a WT (B), and the third dot represents iRECs HNF4a R85W (C; see also A). Not more than five of the most significant terms from each biological domain were plotted for clusters 1, 3, 4, 7, and 8. The labels for biological processes are marked in red, molecular function in blue, and cellular component in green. The size of the spheres corresponds to the number of genes included and the color to the adjusted p value.(G) Heatmap of genes representing mitochondrial gene expression.(H) Left: Seahorse XF Cell Mito Stress Test profile. OCR, oxygen consumption rate. Arrows indicate time for drug injection. A representative experiment is shown. Values represent medians ± SEMs of triplicates. Right: Seahorse parameters calculated as indicated in [Method Details](#sec4.4){ref-type="sec"}. Values are shown as medians ± SEMs of replicates from three independent experiments. One-way ANOVA with post hoc Tukey's test, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.(I) Basal respiration attributed to fatty acid oxidation using etomoxir calculated as indicated in [Method Details](#sec4.4){ref-type="sec"}. Values are shown as medians ± SEMs of replicates from three independent experiments.(J) Bright-field images of lipid droplets stained with oil red O and counterstained with hematoxylin. Scale bar, 10 μm.(K) Quantification of the cell area occupied by lipid droplets (three independent experiments, red lines: medians, Mann-Whitney t test: ^∗∗∗∗^p \< 0.0001).See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Reprogramming to iRECs was achieved with both the wild-type HNF4A and the R85W/FRTS mutation at similar rates (0.66% and 0.69%, respectively). We detected lower mRNA levels of HNF4A R85W expression compared to wild-type ([Figure 7](#fig7){ref-type="fig"}B). Using immunostaining, we also found lower nuclear staining for HNF4A R85W/FRTS protein ([Figures 7](#fig7){ref-type="fig"}C and 7D). However, the overall changes to the transcriptional profile analyzed by RNA sequencing (RNA-seq) were remarkably similar between iRECs reprogrammed using wild-type HNF4A and HNF4A R85W/FRTS, suggesting that the R85W/FRTS mutation retains reprogramming activity and elicits overall similar changes to the gene expression profile from fibroblasts to iRECs ([Figure 7](#fig7){ref-type="fig"}E). Cluster mapping and Gene Ontology (GO)-term enrichment analysis revealed that genes related to mitochondrial function were induced by reprogramming using wild-type HNF4A, but they had a significantly reduced expression in cells reprogrammed using HNF4A R85W/FRTS ([Figures 7](#fig7){ref-type="fig"}F, 7G, [S7](#mmc1){ref-type="supplementary-material"}A, and S7B).

For functional validation, we analyzed the cells with Seahorse XF96 mitochondrial flux analyzer. iRECs reprogrammed with R85W/FRTS showed decreased ATP production and basal respiration together with a strongly impaired maximal respiration ([Figure 7](#fig7){ref-type="fig"}H). Although R85W/FRTS iRECs were able to use fatty acids for basal respiration, the treatment of the cells with the mitochondrial fatty acid uptake inhibitor etomoxir showed that the oxygen consumption rate via the oxidation of fatty acids was relatively lower compared to iREC WT cells ([Figure 7](#fig7){ref-type="fig"}I). Accordingly, due to the change in mitochondrial function, LDs were increased in iREC R85W compared to iRECs WT ([Figures 7](#fig7){ref-type="fig"}J and 7K), confirming the nephrocyte findings in these proximal tubule-like cells.

Discussion {#sec3}
==========

HNF4A is specifically expressed in the kidney in proximal tubules and is required for the terminal differentiation of proximal tubular cells ([@bib23], [@bib35]). However, out of all of the known mutations, only the R85W mutation causes FRTS ([@bib19]). Using fly nephrocytes as a model for proximal tubules, we show here that both dHNF4 KD and overexpression of the FRTS mutation (R167W in flies) causes mitochondrial alterations and LD accumulation. By using a dHNF4-GFP as a reporter protein, we show that the FRTS mutation provokes the nuclear export of the wild-type protomer in a dominant-negative manner, possibly explaining the similarity to the KD. The nuclear export is additionally associated with cytoplasmic aggregate formation, increased autophagy, severe ER morphology changes, and eventually cell death. All of these phenotypes are not seen in the KD, suggesting that they are the result of the aggregate formation. However, they could be observed when expressing wild-type dHNF4 at high levels, suggesting dominant-negative effects in this condition as well. For both dHNF4^R167W/FRTS^ and dHNF4^highOE^, these effects could be rescued by the increase in nuclear levels through dephosphorylation at S169.

Crucial for the understanding of the investigated mutations are structural studies of the HNF4A homodimer/DNA complex, in which the homodimer forms multiple domain-domain junctions and a convergence zone or "nerve center," in which the two LBDs, the upstream positioned DBD, and the hinge region meet. S87 maps precisely to this center, leading to unfavorable charge repulsion upon phosphorylation and disengagement of the quaternary structure needed for DNA binding ([@bib11]). In another nuclear receptor, constitutive androstane receptor (CAR), the corresponding phosphorylation leads to the formation of inactive homodimers ([@bib45]), providing support for this model. As R85 is in close contact with the DNA bases and backbone of the dipartite DR1 element in both upstream and downstream protomers of the homodimer ([@bib11]), the lack of DNA binding in the R85W mutant may promote phosphorylation-dependent conversion of active to inactive homodimers and, finally, nuclear export of both mutant and wild-type protomers.

By contrast, the effects of the MODY mutation R171W resembled those of the phosphorylation-deficient S169A mutant, which is supported by two phosphorylation prediction algorithms (<https://scansite4.mit.edu/4.0/#home> and <http://www.cbs.dtu.dk/services/NetPhos/>), showing that R171W/MODY (or R89W/MODY) but not R167W/FRTS (or R85W/FRTS) reduces the probability for phosphorylation at S169 (or S87). In addition, the available HNF4A structure shows that R89 is closer to the S87 convergence zone compared to R85 ([@bib11]), which may explain that at the R171 (or R89) position, the substitution with the bulky tryptophan could interfere with the S169 (or the mammalian S87) phosphorylation site. Unlike for R167W (or R85W), the reduced DNA binding of R171W (or R89W) may therefore not result in phosphorylation-dependent dominant-negative effects, which is consistent with the haploinsufficiency that has been proposed for most MODY1 mutations ([@bib18]). The reverse conclusion would be that haploinsufficiency alone is not enough to cause FRTS and that dominant-negative effects are required in addition.

As a consequence of the nuclear export due to the dominant-negative mechanism, we uncovered cytotoxic effects that were not seen in the dHNF4 KD and hence are most likely linked with the aggregation of potentially misfolded proteins in the cytoplasm. Our co-labeling with the nuclear envelope marker lamin D shows that the aggregate formation already commences during nuclear export. It can therefore be assumed that the small nuclear pore size causes an accumulation of dHNF4 beneath the nuclear envelope, which in turn favors aggregate formation. Although the order of cytosolic events is not entirely clear, we speculate that the aggregates first pose a challenge for the clearance capacity of the proteasome, which is the normal site of HNF4A degradation ([@bib47]). As a result, the ER may help by translocating chaperones into the cytoplasm to stimulate autophagy, as has been described for BiP and PDI ([@bib10]). Consequently, the ability of the ER to address its own misfolded membrane-bound or luminal proteins could be weakened, thereby causing ER stress. Previously, cytoplasmic aggregates due to dominant-negative mutations or polyQ expansions have been observed in two other nuclear receptors, the thyroid receptor and the androgen receptor, respectively ([@bib8]). In the latter case, the cytoplasmic aggregates were also associated with ER stress ([@bib48]).

While dHNF4 has been shown to act as a regulator of mitochondria gene expression in the fly ([@bib3], [@bib7], [@bib39]), the role of mammalian HNF4A in regulating mitochondrial function has so far been poorly investigated. Using the iREC system, we show here that the R85W mutation affects mitochondria by decreasing the transcription of genes for mitochondrial structure and function. This was accompanied by a reduction in β-oxidation, leading to LD accumulation. As the HNF4A R85W also showed lower mRNA levels, we were unable to assess the contribution of any dominant-negative effects in this model. Also, we could not directly measure any effects of HNF4A R85W on DNA binding as we did in the COS-7 cell system. Nevertheless, both the nephrocyte and iREC results suggest that the effect on mitochondria could be one of the reasons why HNF4A R85W affects the fatty acid-consuming proximal tubules ([@bib25]). In this manner, HNF4A-associated FRTS would be related to mitochondriopathies with isolated Fanconi syndrome or Fanconi syndrome as renal manifestation in more widespread disease ([@bib27], [@bib38], [@bib41]). Given that HNF4A may be regulated by free fatty acids, it would be interesting to explore how extensively HNF4A is controlled by the reabsorption of exogenous fatty acids in proximal tubules (or nephrocytes) and whether fatty acid re-esterification and storage in LDs counteracts HNF4A activation.

In conclusion, our findings establish HNF4A as a master regulator of lipid metabolism in nephrocytes with high relevance for proximal tubular cells. We further provide insight into the molecular basis of HNF4A-associated FRTS that has remained enigmatic since the identification of the first patient with the R85W mutation ([@bib19]). Our results suggest a rationale for treatments aimed at preventing the nuclear export of HNF4A in such patients. As serine phosphorylation in the DBD has been shown to be conserved in many nuclear hormone receptors ([@bib47]), blocking this phosphorylation as a means to increase nuclear activity should also have more general implications.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat monoclonal anti-HARocheCat\# 11867423001, RRID:[AB_390918](nif-antibody:AB_390918){#interref80}Mouse monoclonal anti-ATP5AAbcamCat\# ab14748, RRID:[AB_301447](nif-antibody:AB_301447){#interref85}Rabbit anti-GFPAntibody platform Institut CurieN/AMouse monoclonal lamin Dm0Developmental Studies Hybridoma BankCat\# adl84.12, RRID:[AB_528338](nif-antibody:AB_528338){#interref90}Mouse Mono- and polyubiquitinylated conjugates monoclonal antibody (FK2)Enzo Life SciencesCat\# BML-PW8810, RRID:[AB_10541840](nif-antibody:AB_10541840){#interref95}Mouse monoclonal anti-PDI (1D3)Enzo Life SciencesCat\# ADI-SPA-891, RRID:[AB_10615355](nif-antibody:AB_10615355){#interref100}Rabbit anti-p62/Ref(2)Pgift from T.E. RustenN/AMouse monoclonal anti-V5InvitrogenCat\# R96025, RRID:[AB_159313](nif-antibody:AB_159313){#interref105}**Chemicals, Peptides, and Recombinant Proteins**ParaformaldehydeScience ServicesE15710GlutaraldehydeSigma-AldrichG7526Triton X-100Roth3051.3mounting medium: Roti-Mount FluorCareRothHP19.1X-galThermoScientificR0404polybreneSanta Cruzsc-134220Mayer's Hematoxylin SolutionSigma-AldrichMHS16Oil Red O solutionSigma-AldrichO1391BODIPY 493/503InvitrogenD3922Takyon No ROX SYBR 2X MasterMix blue dTTPEurogentecUF-NSMT-B0701OligomycinSanta Cruzsc-203342FCCPSanta Cruzsc-203578(+)-Etomoxir sodium saltSanta Cruzsc-215009Antimycin ASanta Cruzsc-202467RotenoneSanta Cruzsc-203242**Critical Commercial Assays**QuikChange II Site-directed Mutagenesis kitAgilent Technologies200523QIAzol Lysis ReagentQIAGEN79306RNeasy Plus Universal Mini KitQIAGEN73404QuantiTect Reverse Transcription KitQIAGEN205311Odissey Infrared EMSA KitLi-COR829-07910**Deposited Data**RNA-seq data at GEON/A\#GSE139674**Experimental Models: Cell Lines**Monkey COS-7 cellsFrom V. CantagrelN/AHEK293T/17 cellsATCCCRL-11268Mouse embryonic fibroblasts (MEFs) reprogrammed into induced renal epithelial cells (iRECs)Primary cellsN/A**Experimental Models: Organisms/Strains***D. melanogaster*: Dot-Gal4 driver: w; P\[mw, Dot-Gal4\]From Z. HanN/A*D. melanogaster*: Sns-Gal4 driver: w; P\[mw, sns-GCN-Gal4\]From S. AbmayrN/A*D. melanogaster*: RNAi of GFP: w\[1118\]; P{w\[+mC\] = UAS-GFP.dsRNA.R}142Bloomington Drosophila Stock CenterBDSC \#9330*D. melanogaster*: RNAi of Pkd2: y\[1\] sc\[^∗^\] v\[1\] sev\[21\]; P{y\[+t7.7\] v\[+t1.8\] = TRiP.HMC03263}attP2Bloomington Drosophila Stock CenterBDSC \#51502*D. melanogaster*: RNAi of Hnf4: y\[1\] v\[1\]; P{y\[+t7.7\] v\[+t1.8\] = TRiP.JF02539}attP2Bloomington Drosophila Stock CenterBDSC \#29375*D. melanogaster*: RNAi of midway: y\[1\] sc\[^∗^\] v\[1\] sev\[21\]; P{y\[+t7.7\] v\[+t1.8\] = TRiP.HMC06242}attP40/CyOBloomington Drosophila Stock CenterBDSC \#65963;*D. melanogaster*: GFP- and FLAG-tagged Hnf4: w\[1118\]; PBac{y\[+mDint2\] w\[+mC\] = Hnf4-GFP.FLAG}VK00033Bloomington Drosophila Stock CenterBDSC \#38649*D. melanogaster*: hsp70-GAL4-dHNF4; UAS-nlacZ56From Palanker/ThummelN/A*D. melanogaster*: w; P\[mw, UAS-GFP-mCherry-Atg8\]From Dr. G. JuhaszN/A*D. melanogaster*: RNAi of Hnf4: w1118; P{UAS-Hnf4-RNAi-GD4362}Vienna Drosophila Resource CenterVDRC \#12692*D. melanogaster*: RNAi of ATP6AP2: w; P\[mw,UAS-dsRNA-ATP6AP2\]KK107676Vienna Drosophila Resource CenterVDRC \#105281;*D. melanogaster*: P\[mw, UAS-Hnf4-3xHA\]FlyORFF000144**Oligonucleotides**Probe: IRD700-AAAGGTCCAAAGGGCGCCTMetabionN/AOther oligonucleotides, see [Table S3](#mmc1){ref-type="supplementary-material"}.N/AN/A**Recombinant DNA**Plasmid: pGW.UAS-HNF4-3xHA.attBFlyORFN/AHNF4 alpha (NM_000457) Human Myc-tagged ORF CloneOrigeneCat\# RC217863pWPXLd lentiviral vectorAddgeneCat\# 12258plasmids psPax2AddgeneCat\# 12260pMD2.GAddgeneCat\# 12259**Software and Algorithms**ImageJ<https://imagej.nih.gov/ij/>ImarisN/A<https://imaris.oxinst.com>Galaxy platform[@bib1]<https://usegalaxy.org>**Other**FastQC version 0.11.5N/A<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>Trim Galore! version 0.4.3N/A<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Matias Simons (<matias.simons@institutimagine.org>). All plasmids, oligonucleotides, cell lines, and fly strains generated in this study are available with no restriction.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Fly strains {#sec4.3.1}

*Drosophila melanogaster* stocks were raised on standard cornmeal food. Crosses were reared either at 25°C or at 18°C (e.g., dHNF4^lowOE^). For experiments performed at 29°C (e.g., dHNF4^highOE^), crosses were first kept at 25°C or 18°C until mid-to-late second instar before switching to 29°C for a duration of 24h. For the precise genotype used in each figure, see also [Table S2](#mmc1){ref-type="supplementary-material"}.

### Cell lines {#sec4.3.2}

COS-7 cells (gift by Dr. Cantagrel) were cultured in DMEM (Dulbecco's modified Eagle's medium; GIBCO) supplemented with 10% (v/v) FBS (fetal bovine serum; GIBCO) penicillin/streptomycin and glutamine and were maintained in a humidified atmosphere of 5% CO~2~.

iRECs were cultured on 0.1% gelatin-coated flasks in DMEM (Dulbecco's modified Eagle's medium; Lonza) supplemented with 10% (v/v) FBS (fetal bovine serum; GIBCO) penicillin/streptomycin and glutamine and were maintained in a humidified atmosphere of 5% CO~2~. iRECs were generated from primary embryonic fibroblasts of male mice (MEFs; see below).

Method Details {#sec4.4}
--------------

### Generation of fly strains {#sec4.4.1}

The following stocks were used: *dot*-Gal4 and *sns-*Gal4 drivers, UAS-*GFP*-RNAi, UAS-*Pkd2*-RNAi, UAS-*dHNF4*-RNAi TRIP, UAS-*midway*-RNAi, *hnf4*-HNF4-GFP.Flag and *hsp70*-GAL4-dHNF4; UAS-nlacZ56 were all obtained from Bloomington Stock Center. UAS-*dHNF4*-RNAi, UAS-*ATP6AP2*-RNAi were obtained from VDRC and UAS-HNF4-3XHA was obtained from FlyORF. UAS-GFP-mCherry-Atg8 was a kind gift from Dr. G. Juhasz. For more info see [Key Resources Table](#sec4.1){ref-type="sec"}.

UAS-dHNF4^R167W^-, UAS-dHNF4^R167W/S169A^-, UAS-dHNF4^S169A^- and UAS-dHNF4^R171W^ expressing transgenic flies have been created by site-directed mutagenesis using the QuikChange II Site-directed Mutagenesis kit (Agilent) according to the manufacturer's instructions. Mutagenesis was performed on the pGW.UAS-dHNF4-3xHA.attB plasmid (kindly provided by FlyORF) containing the WT extended gene region of HNF4 using the oligos listed in [Table S3](#mmc1){ref-type="supplementary-material"}. All constructs were injected into flies with the attP landing site at 86FB by Bestgene.

### Immunohistochemistry, lipid droplet labeling and tissue imaging {#sec4.4.2}

Garland nephrocytes from third instar larvae were dissected in PBS, fixed for 20 min in 4% paraformaldehyde in PBS, washed three times in PBS-T (PBS + 0.1% Triton X-100), and incubated overnight at 4°C with primary antibodies diluted in PBS-T. After washing, tissues were incubated for 2 h at room temperature with secondary antibodies (dilution 1:200) and Hoechst (0.5 μg ml^−1^) diluted in PBS-T. Tissues were washed twice in PBS-T followed by a wash in PBS. Tissues were mounted in mounting medium Roti®-Mount FluorCare (Roth). Primary antibodies used were rat anti-HA (1:500, Roche), mouse anti-ATP5A (1:100 Abcam), rabbit anti-GFP (1:500, Antibody platform Institut Curie), mouse lamin Dm0 (5 μg/ml, DSHB), mouse anti-mono- and poly-ubiquitinylated conjugates (1:500, Enzo Life Sciences), mouse anti-PDI (1:500, Enzo Life Sciences), rabbit anti-p62/Ref(2)P (1:5000, gift from T.E. Rusten). Secondary antibodies used were fluorescent conjugated Alexa Fluor 488, Alexa Fluor 555, Alexa Fluor 633, and Alexa Fluor 647 (Invitrogen Molecular Probes). For LD labeling, BODIPY 493/503 (2.5 μg ml^−1^, Molecular Probes) was incubated together with secondary antibodies.

Stainings of pericardial nephrocytes were performed by dissecting the abdomen of 2 days-old female flies in cold PBS. After fixation and washing as mentioned above, tissues were incubated for 2 h at room temperature with Hoechst and horseradish peroxidase (HRP)-Cy3 conjugated (1:100, Jackson Immunoresearch lab) for staining of the cell surface. Tissues were washed and mounted as above.

All images were acquired on a Leica TCS SP8 equipped with a 405-nm laser line and a white light laser with a 63x/1.4 DIC Lambda blue Plan Apochrome objective.

### X-gal staining {#sec4.4.3}

Vials with hsp70-GAL4-dHNF4; UAS-nlacZ56 third instar larvae were heat-shocked in a water bath at 37°C for 30 minutes and allowed to recover for 6 hours at 25°C. Nephrocytes were then dissected in PBS, fixed in 1% glutaraldehyde (Sigma) in PBS for 20 minutes, washed three times in PBS-T and incubated in a pre-warmed 0.2% X-gal solution for 30 minutes at 37°C in the dark. X-gal solution was obtained by adding 8% of X-gal diluted in N,N-dimethylformamide in a pre-warmed X-gal dilution buffer (3mM K~3~Fe\[CN\]~6~, 3 mM K~4~Fe\[CN\]~6~, 0,9 mM MgCl~2~, 0,1% Tween in PBS). Then samples were washed in PBS and mounted on glass slides in mounting medium. Pictures were taken on a Axioplan Zeiss microscope with a 63x Oil objective (N.A. = 1.4).

### Transmission electron microscopy {#sec4.4.4}

For transmission electron microscopy, nephrocytes from third instar larvae were fixed with 2.5% gluataraldehyde (Sigma) in 1X PHEM buffer pH7.3 overnight at 4°C. Specimens were first post-fixed with tannic acid 1% in 0.1M cacodylate buffer pH7.2 for 30', then with 1% osmium tetroxide for 1 hr in 0.1M cacodylate buffer pH7.2 at RT, before pre-embedding the specimens in 4% agar type 9, dehydrating in a graded series of ethanol and embedding in Epon. After heat polymerization, thin sections were cut with a Leica Ultramicrotome Ultracut UC7 sections (60 nm) and stained with uranyl acetate and lead citrate. Images were taken with a Tecnai SPIRIT (FEI-Thermofisher Company at 120 kV accelerating voltage with a camera EAGLE 4K x 4K FEI-Thermofisher Company).

### Cloning and lentivirus production {#sec4.4.5}

For expression in COS-7 cells, mutagenesis was performed using the RC217863 construct (Origene) containing the myc-tagged full-length coding region of human HNF4A2. To this end, the following mutations R85W, R89W, S87A, R85W/S87A were inserted via site-directed mutagenesis (QuikChange II, Stratagene, Santa Clara, CA USA). The oligo pairs used to achieve this are listed in [Table S3](#mmc1){ref-type="supplementary-material"}. The full-length wild-type and mutant cDNA clones were all sequence-verified.

For the lentiviral constructs, mouse transcription factors PAX8 and HNF1b were amplified using gene-specific primers coding sequences and cloned into the pWPXLd lentiviral vector (Addgene). The human transcription factor HNF4A was cloned into a pWPXLd vector containing a V5 epitope tag. For insertion of the R85W mutation into the HNF4A coding sequence, the QuikChange Site-Directed Mutagenesis Kit (Agilent) was applied using the primers listed in [Table S3](#mmc1){ref-type="supplementary-material"}. For lentivirus production, the plasmids pWPXLd, psPax2 and pMD2.G (Addgene) were transfected into HEK293T cells using the calcium phosphate method. After 48h, the supernatant was collected and viruses were precipitated with polyethylene glycol, centrifuged at 6800 rpm for 10 minutes in an Avanti JXN-26 ultracentrifuge (Beckman-Coulter) and stored at −80°C until transduction.

### EMSA {#sec4.4.6}

The doublestranded oligonucleotide probe containing HNF4A-binding site (−192 to −205 from apoA1 promoter from Metabion) labeled with IRDye 700 was used for HNF4A EMSA analysis. The EMSA reaction (20 μL of final volume) contained 1 μL of IRDye 700-labeled DNA probe (50nM) and 2,5 μg of nuclear extracts from COS7 cells transfected with expression plasmids for HNF4A WT or the mutants. The mixture was completed with 2 μL of 10x Binding Buffer, 2 μL of 25mM DTT/2.5% Tween®20 and 1 μL of Poly (dI-dC)1ug/μL from the Odissey® Infrared EMSA kit (LI-COR). The mixture was incubated for 30 min at RT, fractionated on a 4% native polyacrylamide gel containing 50 mMTris, pH 7.5; 0.38 M glycine; and 2 mM EDTA, and imaged by using a Odyssey ® CLx Imaging System.

### iREC generation and immunocytochemistry {#sec4.4.7}

MEFs were reprogrammed to iRECs as previously described ([@bib24]). The only difference to the previous protocol is that only EMX2 was not included as reprogramming factor to increase proximal tubular fate. In short, Ksp-Cre reporter MEFs (Ksp, kidney specific protein, Cadherin-16) were obtained from limbs of E13.5 mouse embryos and kept in MEF medium (MEFM, containing Dulbeccos's modified Eagle's medium (DMEM), 2 mM L-glutamine, penicillin/streptomycin and 10% fetal bovine serum (FBS). After confluency, cells were split 1:4 and transduced lentivirally with the mouse transcription factors PAX8, HNF1B and human transcription factors HNF4A WT or HNF4A R85W. The following combinations of viruses were used for reprogramming: HNF1B + PAX8 (2TF), 2TF + HNF4A WT and 2TF + HNF4A R85W. Lentiviruses were diluted 1:100 to 1:1000 in MEFM containing 8μg mL^-1^ polybrene (Santa Cruz) and transduced for 12 h on 6 consecutive days. Reprogrammed, GFP-positive cells were sorted 14 days after the last viral transduction using a BD FACSAria™ Fusion flow cytometer (Becton Dickinson).

For immunocytochemistry, cells were washed three times in PBS, fixed for 20 min in 4% paraformaldehyde in PBS, blocked for 10 min in PBS + 3% BSA + 0,1% Tween + 0,1% Triton and incubated overnight at 4°C with primary antibodies diluted in PBS + 3% BSA + 0,1% tween + 0,1% triton. After washing, cells were incubated 2 h at room temperature with secondary antibodies (dilution 1:1000) and Hoechst (0.5 μg ml^−1^) diluted in PBS + 3% BSA + 0,1% tween + 0,1% triton. Cells were washed three times in PBS and mounted in Roti®-Mount FluorCare (Roth). As primary antibody mouse anti-V5 (1:400, Invitrogen) was used, and as secondary antibody fluorescent conjugated Alexa Fluor 647 (Invitrogen Molecular Probes). For lipid droplet staining, iRECs were washed three times in PBS, fixed for 25 min in 4% paraformaldehyde in PBS, washed three times in PBS and incubated for 1h with Oil Red O solution (Sigma) diluted with distilled water in a 3:2 ratio. Cells were counterstained with Mayer's Hematoxylin Solution for 1 min and washed three times in tap water.

### Mitochondrial activity measurements {#sec4.4.8}

For measurements of the oxygen consumption rate (OCR) with the Seahorse XF bioanalyzer (Agilent Technologies), iRECs and MEFs were seeded at a density of 20000 cells per well in a collagen coated XFe96 cell culture microplate (Agilent Technologies). 12 hours post-plating cells were balanced for 1 hour in unbuffered XF assay media (Agilent Technologies) supplemented for OCR analysis with 2 mM Glutamine, 10 mM Glucose and 1 mM Sodium Pyruvate. For OCR measurements, compounds were injected during the assay at the following final concentrations: oligomycin (ATP synthase inhibitor to measure respiration associated with cellular ATP production; 1 μM), FCCP (uncoupling agent to measure the maximal respiration capacity; 1 μM), Rotenone and Antimycin A (ETC inhibitors to measure the non-mitochondrial respiration; 1 μM). The data were normalized to protein content measured in each well using BCA assay (Thermo Fisher Scientific) according to the manufacturer's instructions. Seahorse parameters were calculated as followed: last rate measurement before oligomycin injection -- minimum rate measurement after oligomycin injection = ATP production; last rate measurement before first injection -- non-mitochondrial respiration rate = basal respiration; maximum rate measurement after FCCP injection -- non- mitochondrial respiration = maximal respiration. To determine the contribution of fatty acid oxidation to the OCR, etomoxir (CPT1 inhibitor) was injected at a final concentration of 400 μM before the injection of the above-described compounds. Basal respiration of cells treated with vehicle -- Basal respiration of cells treated with etomoxir = basal respiration due to fatty acid oxidation; Basal respiration -- Basal respiration due to fatty acid oxidation = basal respiration independent of fatty acid oxidation. For etomoxir experiments results were normalized by cell area measured with IncuCyte® S3 Live-Cell Analysis System.

### RNA sequencing and qPCR {#sec4.4.9}

Total RNA was extracted with QIAzol Lysis Reagent (QIAGEN) and isolated using the RNeasy Plus Universal Mini Kit (QIAGEN). Library preparation and RNA sequencing were conducted by GATC Biotech AG on an Illumina platform with single-end 50 bp mRNA sequencing. Sequencing data were uploaded to the Galaxy platform ([@bib1]), and [usegalaxy.org](http://usegalaxy.org){#intref0055} server was used to analyze the data. Quality check was assessed with FastQC version 0.11.5 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Reads were trimmed with Trim Galore! version 0.4.3 (<http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/>) and aligned to the genome build GRCm38 using RNA STAR2 version 2.5.2b. Average read count after quality control was 64 million. Gene counts were calculated with featureCounts version 1.6.0 and differentially expressed genes (DEG) between MEF and iREC WT and iREC R85W conditions were determined using DESeq2 version 1.18.1.

For quantitative PCR total RNA was extracted from iRECs which were re-sorted using a strict gating of GFP-positive cells. RNA extraction was performed as described above. For reverse transcription to cDNA the QuantiTect Rev. Transcription Kit (QIAGEN) was applied according to manufacturer's instructions. The qPCR was performed on a Roche LightCycler® 480 instrument using 10 ng of cDNA, gene-specific primers and Takyon SYBR® Master Mix (Eurogentec, Takyon No Rox SYBR® MasterMix dTTP Blue, UF-NSMT-B0701). The primers used are listed in [Table S3](#mmc1){ref-type="supplementary-material"}.

qPCR data were analyzed applying the comparative CT method ([@bib42]). RNA-seq raw data files have been deposited in GEO (Gene expression omnibus).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### Image analysis {#sec4.5.1}

For nephrocytes, percentage of total cell area occupied by LDs was quantified with the "Analyze Particles"-tool of Fiji on thresholded Z stack projections images of BODIPY 493/503. Average nuclear intensity of dHNF4-GFP staining in nephrocytes and whole ATP5A staining intensity in nephrocytes were measured on the nuclear z-plane by the mean intensity using the "Analyze Measure"- tool of Fiji. LD size and density were measured with Imaris by defining the volume of the cell in 3D and then using the Spot Detector tool. For calculating LD density, the number of LDs was normalized to the total volume of the segmented cell.

For IRECs, the average nuclear intensity of HNF4A-V5 was measured on the nuclear z-plane by the mean intensity using the "Analyze Measure"-tool of Fiji. For LD staining, the percentage of the area occupied by LDs in iRECs was quantified using the "Analyze Particles"-tool of Fiji on thresholded images.

### Statistics {#sec4.5.2}

All experiments were repeated at least 3 times with consistent results. Statistical analysis was performed with 2-tailed, unpaired Mann-Whitney's t test for comparison of 2 groups, or one-way ANOVA followed by Tukey's or Dunn's multiple comparison test for multiple comparisons after verifying normality. Statistical analyses were performed using the GraphPad Prism 6.0 program. *P* less than 0.05 was considered significant (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). More details on statistics can be found in each figure legend.

### RNA-seq data analysis {#sec4.5.3}

Downstream analysis was performed using R version 3.5.0. A heatmap of the significant DEG (N = 10963) between all three analyzed conditions was drawn using gplots version 3.0.1 ([Figure 7](#fig7){ref-type="fig"}E). For this, FPKM (Fragments Per Kilobase Million) values were calculated for every gene, base 10 logarithm was computed and z-score standardization was performed. Significant DEG were then divided into 12 clusters using soft clustering tool Mfuzz ([@bib31]). Computed clusters were assigned to eight logically expected expression change patterns ([Figure S7](#mmc1){ref-type="supplementary-material"}). We were not able to assign any genes to logically expected cluster number six representing genes being downregulated in iREC WT and mutation conditions compared to MEFs.

A GO over-representation test was done using Bioconductor package clusterProfiler version 3.8.1 ([@bib53]) and not more than five most significant terms from each biological domain of clusters one, three, four, seven and eight were plotted ([Figure 7](#fig7){ref-type="fig"}F). With genes representing mitochondrial gene expression GO term (GO:0140053) a heatmap was plotted as outlined above.

Data and Code Availability {#sec4.6}
--------------------------

RNA-seq datasets have been deposited in GEO (Gene expression omnibus) under the accession number \#[GSE139674](ncbi-geo:GSE139674){#intref0070}.
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